Maruho Europe
CompanyUnited Kingdom
Maruho Europe develops one asset, in phase 3 (M518101 in plaque psoriasis). Mostly small molecule acting on VDR; based in the United Kingdom.
- 1
- Asset
- Furthest stage
- Phase 3
- 3
- Trials
- 1
- Signal
Pipeline
1Vitamin D receptor agonist formulation for skin disorders
Phase 3, Small molecule, VDR, plaque psoriasis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials3
- Signals1
- Similar companies6